Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.
Breast cancer (BC) screening has been developed to detect earlier stage tumors associated with better prognosis. The aim of study was to evaluate the impact of BC screening on therapeutic management of patients with first operable BC, and on costs, patients' needs, and working life. OPTISOINS01...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6107193?pdf=render |
| _version_ | 1818151577189351424 |
|---|---|
| author | Amélie Cariou Roman Rouzier Sandrine Baffert Anne-Laure Soilly Delphine Hequet |
| author_facet | Amélie Cariou Roman Rouzier Sandrine Baffert Anne-Laure Soilly Delphine Hequet |
| author_sort | Amélie Cariou |
| collection | DOAJ |
| description | Breast cancer (BC) screening has been developed to detect earlier stage tumors associated with better prognosis. The aim of study was to evaluate the impact of BC screening on therapeutic management of patients with first operable BC, and on costs, patients' needs, and working life. OPTISOINS01 was a multicenter, prospective observational study which aimed to identify the main care pathway of early BC. Among patients aged from 50 to 74 years-old, 2 groups were defined: the "Clinical signs" group and the "Screening" group (national organized screening and individual screening). We compared between these 2 groups: locoregional and systemic treatments, direct medical and non-medical costs from a National Health Insurance perspective, patients' needs assessed by the validated SCNS-BR8 "breast cancer" module of the SCNS-SF34 supportive care needs survey and the duration of sick leave. The "Clinical signs" group included 89 patients, while the"Screening" group included 290 patients. More axillary lymph node dissections and radical breast surgery were performed in the "Clinical signs". The rate of adjuvant chemotherapy was dramatically higher in the "Clinical signs" group. The median direct medical costs of the "Screening" group were €11,860 (€3,643-€41,030) per year and per patient, much lower than in the "Clinical signs" group (€14,940; €5,317-€41,070). Finally, needs specifically assessed by the SCNS-BR8 questionnaire were significantly higher for the postoperative and post-adjuvant periods in the "Clinical signs" group. This study highlighted the benefit of BC screening in terms of reduced therapies and positive impact on work and social life. |
| first_indexed | 2024-12-11T13:41:02Z |
| format | Article |
| id | doaj.art-80bd09aa20d34c6f91dfe37a1d30e099 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T13:41:02Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-80bd09aa20d34c6f91dfe37a1d30e0992022-12-22T01:04:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01138e020238510.1371/journal.pone.0202385Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.Amélie CariouRoman RouzierSandrine BaffertAnne-Laure SoillyDelphine HequetBreast cancer (BC) screening has been developed to detect earlier stage tumors associated with better prognosis. The aim of study was to evaluate the impact of BC screening on therapeutic management of patients with first operable BC, and on costs, patients' needs, and working life. OPTISOINS01 was a multicenter, prospective observational study which aimed to identify the main care pathway of early BC. Among patients aged from 50 to 74 years-old, 2 groups were defined: the "Clinical signs" group and the "Screening" group (national organized screening and individual screening). We compared between these 2 groups: locoregional and systemic treatments, direct medical and non-medical costs from a National Health Insurance perspective, patients' needs assessed by the validated SCNS-BR8 "breast cancer" module of the SCNS-SF34 supportive care needs survey and the duration of sick leave. The "Clinical signs" group included 89 patients, while the"Screening" group included 290 patients. More axillary lymph node dissections and radical breast surgery were performed in the "Clinical signs". The rate of adjuvant chemotherapy was dramatically higher in the "Clinical signs" group. The median direct medical costs of the "Screening" group were €11,860 (€3,643-€41,030) per year and per patient, much lower than in the "Clinical signs" group (€14,940; €5,317-€41,070). Finally, needs specifically assessed by the SCNS-BR8 questionnaire were significantly higher for the postoperative and post-adjuvant periods in the "Clinical signs" group. This study highlighted the benefit of BC screening in terms of reduced therapies and positive impact on work and social life.http://europepmc.org/articles/PMC6107193?pdf=render |
| spellingShingle | Amélie Cariou Roman Rouzier Sandrine Baffert Anne-Laure Soilly Delphine Hequet Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. PLoS ONE |
| title | Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. |
| title_full | Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. |
| title_fullStr | Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. |
| title_full_unstemmed | Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. |
| title_short | Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. |
| title_sort | multidimensional impact of breast cancer screening results of the multicenter prospective optisoins01 study |
| url | http://europepmc.org/articles/PMC6107193?pdf=render |
| work_keys_str_mv | AT ameliecariou multidimensionalimpactofbreastcancerscreeningresultsofthemulticenterprospectiveoptisoins01study AT romanrouzier multidimensionalimpactofbreastcancerscreeningresultsofthemulticenterprospectiveoptisoins01study AT sandrinebaffert multidimensionalimpactofbreastcancerscreeningresultsofthemulticenterprospectiveoptisoins01study AT annelauresoilly multidimensionalimpactofbreastcancerscreeningresultsofthemulticenterprospectiveoptisoins01study AT delphinehequet multidimensionalimpactofbreastcancerscreeningresultsofthemulticenterprospectiveoptisoins01study |